|
|
| | RUBOXISTAURIN HYDROCHLORIDE Basic information |
| Product Name: | RUBOXISTAURIN HYDROCHLORIDE | | Synonyms: | Ruboxistaurin Hydrochloride;(9S)-9-[(DiMethylaMino)Methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-DiMethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione Hydrochloride;(S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione monohydrochloride;Ruboxistaurin HCl;Ruboxistaurin(LY333531HCl);LY 333531 hydrochloride - Ruboxistaurin;Ruboxistaurin hydrochloride (LY333531);Ruboxistaurin HCl(LY333531 ) | | CAS: | 169939-93-9 | | MF: | C28H29ClN4O3 | | MW: | 505.02 | | EINECS: | | | Product Categories: | Amines;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 169939-93-9.mol |  |
| | RUBOXISTAURIN HYDROCHLORIDE Chemical Properties |
| alpha | D25 -28.7° (c = 1.0 in ethanol) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO: soluble10mg/mL, clear | | form | powder | | color | orange-red |
| | RUBOXISTAURIN HYDROCHLORIDE Usage And Synthesis |
| Description | LY333531 is an inhibitor of PKCβ (IC50s = 4.7 and 5.9 nM for PKCβ1 and PKCβ2, respectively). It is selective for PKCβ1 and PKCβ2 over PKCα, -γ, -δ, -ε, -ζ, and -η (IC50s = 360, 300, 250, >100,000, and 52 nM, respectively). LY333531 also inhibits glycogen synthase kinase 3β (GSK3β; IC50 = 39.4 nM). It inhibits neutrophil extracellular trap (NET) formation induced by phorbol 12-myristate 13-acetate (PMA; ) in primary human neutrophils when used at a concentration of 1 μM. LY333531 increases the mechanical nociceptive threshold in a rat model of diabetic hyperalgesia induced by streptozotocin (STZ; ). | | Uses | Ruboxistaurin is a protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial growth factor (VEGF). Ruboxistaurin is used in treatment of diabetic microvascular complications. | | Uses | A protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial growth factor (VEGF). It is used in treatment of diabetic microvascular comp |
| | RUBOXISTAURIN HYDROCHLORIDE Preparation Products And Raw materials |
|